Company: BNBX
Filing Date: 2025-12-22
Form Type: S-1/A
Source: 0001104659-25-123402
Chunk: 20

Company: BNB PLUS CORP.
Filing Date: 2025-12-22
Form: S-1/A
Chunk 20
---
-fidelity synthetic DNA without the use of living cells. The resulting DNA can be         
 used in the manufacturing of various biotherapeutics, serve as the starting material for         
 mRNA therapeutics and vaccines, and as a critical component of IVDs.                             |

| · | LineaRNAP™:                                                                                  
 A next-generation RNA polymerase (“RNAP”) used to transform DNA into mRNA. Our               
 RNAP is engineered with a patented DNA-binding domain that we believe results in high mRNA   
 yields and reduced double-stranded RNA (dsDNA) contamination, a common problematic byproduct 
 produced during mRNA production.                                                             |

| · | LineaIVT™:                                                                                  
 An integrated system that combines the Company’s LineaDNA and LineaRNAP technologies.       
 This innovative solution simplifies the mRNA production workflow resulting in a streamlined 
 production process with fewer impurities than traditional methods.                          |

Our business strategy is to continue advancing our nucleic acid production solutions to support potential future sales and/or licensing agreements of our LineaRx business and/or its technology solutions with third-party partners. LineaDNA LineaDNA is our core enabling technology for rapid, efficient, and scalable cell-free manufacture of high-fidelity synthetic DNA sequences used in the manufacturing of a broad range of biotherapeutics. The LineaDNA platform enzymatically produces a linear form of synthetic DNA we call “LineaDNA” that is an alternative to plasmid-based DNA manufacturing technologies that have supplied the DNA used in biotherapeutics for the past 40 years. LineaDNA can be quickly produced in batches ranging from milligram to grams under a variety of controlled manufacturing processes including research use only (“RUO”), good laboratory practices (“GLP”) and good manufacturing practices (“GMP”). We believe LineaDNA holds several important advantages over existing cell-based plasmid DNA manufacturing platforms. Plasmid-based DNA manufacturing is based on the complex, costly and time-consuming biological process of amplifying DNA in living bacterial cells. Once amplified, the DNA must be separated from the living cells and other process contaminants via multiple rounds of purification, adding further complexity and costs. Unlike plasmid-based DNA manufacturing, LineaDNA does not require living cells and instead amplifies DNA via the exponential enzymatic process of PCR. The LineaDNA platform is simple, scalable and can rapidly produce large quantities of DNA with minimal purification steps. Preclinical studies conducted by the Company have shown that LineaDNA is substitutable for plasmid DNA in numerous biotherapeutic applications, including